ライフサイエンスコーパス: alfa

1 ly glycosylated protein therapeutic (Epoetin Alfa).

2 ping an Aptamer-nanozyme lateral flow assay (ALFA).

3 h lower doses or were switched to agalsidase-alfa.

4 uring dose reduction or switch to agalsidase-alfa.

5 mild adverse events unrelated to sebelipase alfa.

6 in human serum through developed competitive ALFA.

7 ved four once-weekly infusions of sebelipase alfa (0.35, 1, or 3 mg.kg(-1) ) before transitioning to

8 the Acute Leukemia French Association 0702 (ALFA-0702) trial, MRD evaluation was available in 152 pa

9 2010 for CIN lesions used topical interferon alfa 1 million IU/ml drops 4 times daily and retinoic ac

10 Patients received asfotase alfa (1 mg/kg three times per week subcutaneously, adjus

11 r (150 mg once daily, orally), peginterferon alfa 2a (180 mug once weekly, subcutaneous injection) or

12 Simeprevir once daily with peginterferon alfa 2a and ribavirin shortens therapy in treatment-naiv

13 Pegylated interferon (peginterferon) alfa 2a or 2b plus ribavirin regimens were the standard

14 inhibitor versus placebo, plus peginterferon alfa 2a or 2b plus ribavirin was assessed in treatment-n

15 for 12 weeks, followed by just peginterferon alfa 2a or 2b plus ribavirin.

16 placebo (once daily, orally), peginterferon alfa 2a or 2b, plus ribavirin (placebo group) for 12 wee

17 dition of simeprevir to either peginterferon alfa 2a or peginterferon alfa 2b plus ribavirin improved

18 irin for 12 weeks, followed by peginterferon alfa 2a plus ribavirin (placebo group).

19 irin for 12 weeks, followed by peginterferon alfa 2a plus ribavirin (simeprevir group), or placebo or

20 50 mg once daily, orally) plus peginterferon alfa 2a plus ribavirin for 12 weeks, followed by peginte

21 group), or placebo orally plus peginterferon alfa 2a plus ribavirin for 12 weeks, followed by peginte

22 S3/4A protease inhibitor, plus peginterferon alfa 2a plus ribavirin were assessed in treatment-naive

23 event profiles associated with peginterferon alfa 2a plus ribavirin.

24 virin was superior to placebo, peginterferon alfa 2a, and ribavirin (SVR12 in 210 [80%] patients of 2

25 Treatment with simeprevir, peginterferon alfa 2a, and ribavirin was superior to placebo, peginter

26 All patients received peg-IFN alfa-2a (180 microg/week) plus RBV (1000-1200 mg/day) fo

27 (0.5 mg maximum) for 48 weeks; peginterferon alfa-2a (180 ug/1.73m(2) subcutaneously) once-weekly was

28 eneration protease inhibitor), peginterferon alfa-2a (40 KD), and ribavirin in these patients.

29 nts received mericitabine plus peginterferon alfa-2a (40KD)/ribavirin were analyzed by population and

30 ir (SOF), ribavirin (RBV) and peg-interferon-alfa-2a (peg-IFN-alfa-2a) as well as the combination of

31 oxil fumarate (TDF) and pegylated interferon alfa-2a (pegIFN) in patients with chronic HBV infection

32 vir in combination with pegylated interferon alfa-2a (peginterferon) and ribavirin in non-cirrhotic t

33 crog/kg/week or 1 microg/kg/week, or peg-IFN alfa-2a 180 microg/week plus RBV.

34 ks followed by the addition of peginterferon alfa-2a 180 ug/week to entecavir for an additional 40 we

35 ek (for arm B) of pegylated (Peg) interferon alfa-2a added to their current ART regimen.

36 atients treated for 48 weeks with either PEG-alfa-2a and adefovir (ADV) or either drug alone in the H

37 U/mL) were treated with pegylated interferon alfa-2a and adefovir for 48 weeks.

38 and safety of pegylated interferon (peg-IFN) alfa-2a and peg-IFN alfa-2b plus ribavirin (RBV) in chil

39 (Group A, 11 patients) or with peginterferon alfa-2a and ribavirin (Group B, 10 patients) for 24 week

40 tients) or in combination with peginterferon alfa-2a and ribavirin (group B, 10 patients) for 24 week

41 vir in combination with pegylated interferon alfa-2a and ribavirin (Peg-IFN/RBV) for 15 days (TPR; n

42 d 2:1:1 to receive 48 weeks of peginterferon alfa-2a and ribavirin (PegIFN/RBV) in combination with f

43 to receive 24 weeks of pegylated interferon alfa-2a and ribavirin (PegIFN/RBV) in combination with p

44 200 mg once daily) plus pegylated interferon alfa-2a and ribavirin (PegIFNalpha-2a and RBV) for 4 wee

45 atients were then treated with peginterferon alfa-2a and ribavirin alone for 12 weeks if their level

46 weeks followed by 36 weeks of peginterferon alfa-2a and ribavirin alone.

47 responders with simeprevir and peginterferon alfa-2a and ribavirin and telaprevir and peginterferon a

48 virologic response (SVR) after peginterferon alfa-2a and ribavirin combination therapy in these patie

49 nce a day) in combination with peginterferon alfa-2a and ribavirin for 12 weeks followed by 36 weeks

50 y or 750 mg every 8 hours plus peginterferon alfa-2a and ribavirin for 12 weeks; patients were then t

51 ) who received sofosbuvir plus peginterferon alfa-2a and ribavirin for 8 weeks had a sustained virolo

52 or 12 weeks or sofosbuvir plus peginterferon alfa-2a and ribavirin for 8 weeks.

53 non-inferior to telaprevir and peginterferon alfa-2a and ribavirin for SVR12 (54% [203/379] vs 55% [2

54 eek regimen of sofosbuvir plus peginterferon alfa-2a and ribavirin in 327 patients with HCV genotype

55 Peginterferon alfa-2a and ribavirin therapy provides good HCV SVR dura

56 All patients received pegylated interferon alfa-2a and ribavirin therapy.

57 d ribavirin and telaprevir and peginterferon alfa-2a and ribavirin treatment, respectively.

58 t least one previous course of peginterferon alfa-2a and ribavirin treatment.

59 Simeprevir and peginterferon alfa-2a and ribavirin was non-inferior to telaprevir and

60 Simeprevir once a day with peginterferon alfa-2a and ribavirin was well tolerated in HCV genotype

61 very 12 hours) or placebo plus peginterferon alfa-2a and ribavirin, followed by peginterferon alfa-2a

62 clatasvir, in combination with peginterferon alfa-2a and ribavirin, is a well tolerated and effective

63 of placebo, each combined with peginterferon alfa-2a and ribavirin.

64 evir, each in combination with peginterferon alfa-2a and ribavirin.

65 -2a and ribavirin, followed by peginterferon alfa-2a and ribavirin.

66 n placebo received 48 weeks of peginterferon alfa-2a and ribavirin.

67 treatment intensification with peginterferon alfa-2a and ribavirin.

68 iral agents were combined with peginterferon alfa-2a and ribavirin.

69 duction is needed, even though pegylated IFN-alfa-2a and ruxolitinib might be useful in particular se

70 INTERPRETATION: Pegylated interferon alfa-2a can induce durable haematological and molecular

71 Peginterferon alfa-2a could be an effective therapy for extensive or t

72 of these groups also received peginterferon alfa-2a for 4, 8, or 12 weeks.

73 Whether prolonged therapy with peginterferon alfa-2a for 96 weeks and combination therapy with tenofo

74 Peg-interferon alfa-2a immunotherapy resulted in control of HIV replica

75 fficacy of REP 2139 and pegylated interferon alfa-2a in patients with chronic HBV and hepatitis D vir

76 Pegylated interferon alfa-2a induced haematological (66 [80%] of 83 patients)

77 Pegylated interferon alfa-2a is an immunomodulatory agent used to treat polyc

78 At week 12 of Peg-interferon alfa-2a monotherapy, viral suppression was observed in 9

79 nd 180 mug subcutaneous pegylated interferon alfa-2a once per week for 15 weeks, then monotherapy wit

80 onotherapy with 180 mug pegylated interferon alfa-2a once per week for 33 weeks.

81 Clinical trials examining peg-IFN alfa-2a or peg-IFN alfa-2b plus RBV among persons ages 3

82 ombination treatment of SOF, RBV and peg-IFN-alfa-2a or SOF and RBV.

83 20 (33%) of 61 patients in the peginterferon alfa-2a plus placebo group (odds ratio 1.84, 95% CI 0.86

84 a plus TDF group and 25 in the peginterferon alfa-2a plus placebo group).

85 plus TDF group and 485 in the peginterferon alfa-2a plus placebo group).

86 -2a plus TDF and 61 to receive peginterferon alfa-2a plus placebo, including 48 (40%) patients with c

87 immediate vs delayed treatment with peg-IFN alfa-2a plus RBV in participants with recent injection d

88 elihood of SVR than was pegylated interferon alfa-2a plus ribavirin (absolute difference, 8 percentag

89 plus ribavirin for 12 weeks or peginterferon alfa-2a plus ribavirin for 24 weeks.

90 -week combination therapy with peginterferon alfa-2a plus ribavirin.

91 drugs treated with directly observed peg-IFN alfa-2a plus self-administered RBV, SVR is comparable to

92 ctly observed pegylated interferon (peg-IFN) alfa-2a plus self-administered ribavirin (RBV) for the t

93 A-positive patients to receive peginterferon alfa-2a plus TDF and 61 to receive peginterferon alfa-2a

94 wo treatment groups (23 in the peginterferon alfa-2a plus TDF group and 25 in the peginterferon alfa-

95 944 adverse events (459 in the peginterferon alfa-2a plus TDF group and 485 in the peginterferon alfa

96 28 (48%) of 59 patients in the peginterferon alfa-2a plus TDF group and in 20 (33%) of 61 patients in

97 : Combined REP 2139 and pegylated interferon alfa-2a therapy is safe, well tolerated, and establishes

98 nitial starting dose of pegylated interferon alfa-2a was 450 mug subcutaneously once per week, but wa

99 eks, ART was interrupted, and Peg-interferon alfa-2a was continued for up to 12 weeks (the primary en

100 on (1:1) to receive 180 mug of peginterferon alfa-2a weekly plus either TDF (300 mg once daily) or pl

101 in (RBV) and peg-interferon-alfa-2a (peg-IFN-alfa-2a) as well as the combination of SOF and RBV for t

102 The combination of danoprevir, peginterferon alfa-2a, and ribavirin leads to high rates of SVR in pat

103 The strength of peginterferon alfa-2a-induced IFIG response significantly correlated w

104 ential prognostic indicator in peginterferon alfa-2a-treated patients with HIV infection.

105 posi sarcoma were treated with peginterferon alfa-2a.

106 were treated for 12 weeks with peginterferon alfa-2a.

107 ore the introduction of pegylated interferon alfa-2a.

108 150 mg once daily) with pegylated interferon alfa-2a/ribavirin (peg-IFN/RBV) for 12 weeks.

109 nrolling patients treated with peginterferon alfa-2a/ribavirin (PEG/RBV) with or without TVL or BOC.

110 NS3-4A protease inhibitor) and peginterferon alfa-2a/ribavirin (PR) in patients with genotype 1 chron

111 treated with mericitabine plus peginterferon alfa-2a/ribavirin in PROPEL and JUMP-C, virologic breakt

112 ed with a total of 48 weeks of peginterferon alfa-2a/ribavirin.

113 = 58 in the final analysis) or peginterferon alfa 2b (1.5 mcg/kg/wk), ribavirin (1000-1200 mg/day), a

114 ither peginterferon alfa 2a or peginterferon alfa 2b plus ribavirin improved SVR in treatment-naive p

115 l cimetidine (15% vs 5%), topical interferon alfa-2b (0% vs 1%), cryotherapy (0% vs 3%), photodynamic

116 ith adjuvant topical or injection interferon alfa-2b (38% vs 15%).

117 High-dose interferon alfa-2b (HDI) has emerged as a potentially effective adj

118 High-dose interferon alfa-2b (HDI) was administered concurrently, including i

119 second-line therapy, he received interferon alfa-2b (IFN--2b) 2.7 MU daily, which he tolerated well.

120 were randomly assigned to receive interferon alfa-2b (IFN-alpha-2b) 20 MIU/m(2) intravenously (IV) da

121 survival (PFS) of bevacizumab or interferon alfa-2b (IFN-alpha-2b) added to octreotide among patient

122 , cisplatin, vinblastine, interleukin-2, IFN alfa-2b (IFN-alpha-2b) and granulocyte colony-stimulatin

123 aintenance therapy with pegylated interferon alfa-2b (IFN-alpha-2b) in patients whose osteosarcoma sh

124 Adjuvant pegylated interferon alfa-2b (PEG-IFN-alpha-2b) was approved for treatment of

125 Boceprevir (BOC) added to peginterferon alfa-2b (PegIFN) and ribavirin (RBV) significantly incre

126 py with boceprevir plus pegylated interferon alfa-2b (peginterferon) and ribavirin, which increases r

127 were treated for up to 48 weeks with peg-IFN alfa-2b 1.5 microg/kg/week or 1 microg/kg/week, or peg-I

128 e combination of tremelimumab and interferon alfa-2b acting via different and possibly synergistic me

129 y offer a superior alternative to interferon alfa-2b alone in treating CIN.

130 eriod compared with studies using interferon alfa-2b alone.

131 eve that combination treatment of interferon alfa-2b and retinoic acid may offer a superior alternati

132 ising efficacy and safety of ropeginterferon alfa-2b and support the development of the drug in a ran

133 g that already low levels of ropeginterferon alfa-2b are sufficient to induce significant hematologic

134 nt adenovirus that delivers human interferon alfa-2b cDNA into the bladder epithelium, and a novel in

135 The unique feature of ropeginterferon alfa-2b is a longer elimination half-life, which allows

136 pical all-trans retinoic acid and interferon alfa-2b may act synergistically.

137 were normalized by treatment with interferon alfa-2b or after expression of wild-type DOCK2.

138 trials examining peg-IFN alfa-2a or peg-IFN alfa-2b plus RBV among persons ages 3-18 years with HCV

139 ted interferon (peg-IFN) alfa-2a and peg-IFN alfa-2b plus ribavirin (RBV) in children and adolescents

140 Dual therapy with pegylated interferon alfa-2b plus ribavirin was associated with a lower likel

141 nt oral cimetidine and/or topical interferon alfa-2b provide satisfactory tumor control.

142 evaluating the role of high-dose interferon alfa-2b therapy (HDI) or completion lymph node dissectio

143 ment of topical retinoic acid and interferon alfa-2b was effective in treating lesions with minimal s

144 eks, and lower doses of pegylated interferon alfa-2b were less effective than standard doses (2 to 4

145 cimetidine, topical or injection interferon alfa-2b, and photodynamic therapy.

146 eron (IFN) alpha-2b isoform, ropeginterferon alfa-2b.

147 urther exploration (e.g., donepezil, epoetin alfa); (3) drugs with alternative biologic explanations

148 d groups: 1) nebulized surfactant (poractant alfa 400 mg/kg) via a customized investigational eFlow-N

149 nd for low-dose radioiodine plus thyrotropin alfa (84.3%) versus high-dose radioiodine plus thyroid h

150 %) or high-dose radioiodine plus thyrotropin alfa (90.2%).

151 Olipudase alfa, a recombinant form of human ASM, is being develope

152 Talactoferrin alfa, a recombinant form of human lactoferrin, has simil

153 multi-modal neonatal brain MR images, named ALFA (Accurate Learning with Few Atlases).

154 A decade after drotrecogin alfa (activated) (DAA) was released on the market worldw

155 nt human activated protein C, or drotrecogin alfa (activated) (DrotAA), for the treatment of patients

156 ortality was reduced by 18% with drotrecogin alfa (activated) compared with controls (relative risk 0

157 mental and analytical studies of drotrecogin alfa (activated) in adults with severe sepsis until Jan

158 lity for single-group studies of drotrecogin alfa (activated) was 41% (95% CI 35-48), and was higher

159 The serious bleeding rate with drotrecogin alfa (activated) was 5.6% (4.5-6.9), which was higher th

160 Drotrecogin alfa (activated) was approved for use in severe sepsis i

161 Real-life use of drotrecrogin alfa (activated) was associated with significant reducti

162 ssion showed greater benefits of drotrecogin alfa (activated) with increasing control mortality (p=0.

163 risk of bleeding associated with drotrecogin alfa (activated).

164 f enzyme-replacement therapy with sebelipase alfa (administered intravenously at a dose of 1 mg per k

165 AlfA, an ALP that pushes plasmids apart in Bacillus, rel

166 howed 1 year safety and efficacy of asfotase alfa, an enzyme replacement therapy.

167 These data establish that sebelipase alfa, an investigational enzyme replacement, in patients

168 ith hydroxyurea as first-line and interferon-alfa and busulfan as second-line drugs of choice.

169 ard of care has been subcutaneous interferon alfa and oral ribavirin for 24-72 weeks.

170 ) at 6 months did not differ between epoetin alfa and placebo, but declines in stroke volume (-5+/-8

171 boceprevir or telaprevir with peginterferon-alfa and ribavirin for the treatment of patients infecte

172 Because pegylated interferon alfa and ribavirin remain a key part of the treatment re

173 typical of those expected from peginterferon alfa and ribavirin therapy.

174 uccessful eradication of HCV with interferon alfa and ribavirin was shown to improve some of these ex

175 laprevir, combined with pegylated interferon alfa and ribavirin, is an efficacious approach to treat

176 infection include pegylated interferon (IFN)-alfa and ribavirin.

177 pg/mL for EPOzeta, 30 pg/mL for darbepoetin alfa, and 80 pg/mL for C.E.R.A.

178 d the recombinant forms EPOzeta, darbepoetin alfa, and C.E.R.A., from human urine is described, emplo

179 eeks (n = 199); or sofosbuvir, peginterferon-alfa, and ribavirin for 12 weeks (n = 197).

180 he investigational factor Xa decoy andexanet alfa, and the synthetic small molecule ciraparantag.

181 with CHIKV in the presence of RBV and/or IFN alfa, and viral production was quantified by plaque assa

182 Andexanet alfa (andexanet) is a recombinant modified human factor

183 a stroke, 101/2012 (5.0%) in the darbepoetin alfa arm and 53/2026 (2.6%) in the placebo arm (hazard r

184 udies illustrate the promise of RBV plus IFN alfa as a potential therapeutic strategy for the treatme

185 clinically relevant regimens of RBV and IFN alfa as combination therapy.

186 ties of ribavirin (RBV) and interferon (IFN) alfa as monotherapy and combination therapy against chik

187 bazine, interleukin-2 (IL-2), and interferon alfa as part of a clinical trial, he developed headaches

188 In the HFIM system, RBV plus IFN alfa at clinical exposures resulted in a 2.1-log10 decre

189 Interferon alfa-based regimens used to treat recurrent hepatitis C

190 In 2017, cerliponase alfa (Brineura), a tripeptidyl peptidase enzyme replacem

191 Free AlfB breaks up AlfA bundles and promotes filament turnover.

192 As ALFA can learn from partially labelled datasets, it can

193 a suggest that short-term treatment with IFN alfa combined with RBV decreases HIV expression, in part

194 essure failure rate with nebulized poractant alfa compared with that with the intubation surfactant e

195 ALFA could also be applied to other imaging modalities a

196 ssess the long-term tolerability of asfotase alfa, defined as the number of patients with one or more

197 Treatment with darbepoetin alfa did not improve clinical outcomes in patients with

198 outcome trial found that the ESA darbepoetin alfa did not improve long-term outcomes in patients with

199 lobin level, platelet count, and darbepoetin alfa dose did not differ between those with and without

200 After stimulation with thyrotropin alfa, dosimetry with iodine-124 positron-emission tomogr

201 tenance therapy with rituximab or interferon alfa, each given until progression.

202 phase and a single dose (60,000 U of epoetin alfa) efficacy phase; the Reduction of Infarct Expansion

203 AlfA elongates unidirectionally and is not dynamically u

204 rity study to evaluate the impact of epoetin alfa (EPO) on tumor outcomes when used to treat anemia i

205 Epoetin alfa (EPO) robustly induced bone marrow erythroferrone (

206 28B(rs12979860), serum 25OH-vitamin D, serum alfa-fetoprotein (AFP)) were performed on a cohort of 20

207 evated serum human chorionic gonadotropin or alfa-fetoprotein concentrations that matched Internation

208 , patients' human chorionic gonadotropin and alfa-fetoprotein concentrations were measured at day 18-

209 decline in human chorionic gonadotropin and alfa-fetoprotein continued BEP (Fav-BEP group) for 3 add

210 rosome complex that nucleates and stabilizes AlfA filaments.

211 the extension phase; nine received asfotase alfa for at least 6 years and completed the study, with

212 ntile hypophosphatasia treated with asfotase alfa for up to 7 years showed early, sustained improveme

213 ne in all patients who received any asfotase alfa (full-analysis population).

214 d in 153 patients (13.5%) in the darbepoetin alfa group and 114 patients (10.0%) in the placebo group

215 red in 42 patients (3.7%) in the darbepoetin alfa group and 31 patients (2.7%) in the placebo group (

216 of 1136 patients (50.7%) in the darbepoetin alfa group and 565 of 1142 patients (49.5%) in the place

217 in 11 of 36 patients (31%) in the sebelipase alfa group and in 2 of 30 (7%) in the placebo group (P=0

218 e group (P=0.007) and 23% in the thyrotropin alfa group versus 30% in the group undergoing thyroid ho

219 g the high dose and 87.1% in the thyrotropin alfa group versus 86.7% in the group undergoing thyroid

220 acebo group (hazard ratio in the darbepoetin alfa group, 1.01; 95% confidence interval, 0.90 to 1.13;

221 s, hevein-like peptides, snakins, cyclotide, alfa-hairpinins and LTPs.

222 review suggested that biosimilars of epoetin alfa have similar efficacy and safety to reference produ

223 after 4 years, 58%, vs. 29% with interferon alfa; hazard ratio for progression or death, 0.55; 95% c

224 erall survival (OS) for high-dose interferon alfa (HDI) and ipilimumab at 10 mg/kg (ipi10).

225 reatment of HDV is with pegylated interferon alfa; however, response rates are poor.

226 epatitis C virus (HCV) infection, interferon alfa (IFN-alpha) alters expression of IFN-stimulated gen

227 epatitis C virus (HCV) infection, interferon alfa (IFN-alpha) alters expression of IFN-stimulated gen

228 treatment, 38% were treated with interferon alfa (IFNalpha)-based therapies, and 33% received nucleo

229 ndings do not support the use of darbepoetin alfa in these patients.

230 nd ribavirin, with and without peginterferon-alfa, in treatment-experienced patients with cirrhosis a

231 e of patients with spontaneous or interferon alfa-induced resolution of acute or chronic infections,

232 edicted FEV1, and chronic therapies (dornase alfa, inhaled antibiotics, inhaled and oral corticostero

233 Andexanet alfa is a modified recombinant inactive form of human fa

234 Talactoferrin alfa is a recombinant form of the human glycoprotein, la

235 Switching to agalsidase-alfa is safe, but microalbuminuria may progress and Fabr

236 Peginterferon alfa is the only recommended therapy, but it produces un

237 tively, when randomly assigned to interferon alfa (n = 97).

238 ety of the recombinant human LAL, sebelipase alfa, nine patients received four once-weekly infusions

239 Serious adverse events related to asfotase alfa occurred in three (27%) patients (severe chronic he

240 of stroke included assignment to darbepoetin alfa (odds ratio 2.1; 95% confidence interval, 1.5-2.9),

241 We evaluated the effects of darbepoetin alfa on clinical outcomes in patients with systolic hear

242 notherapy or in combination with Darbepoetin alfa on iron metabolism and anemia resolution in 2 diffe

243 However, the short-term impact of IFN alfa on persistent HIV and its effects on immune activat

244 fect of 5 years of treatment with agalsidase alfa or agalsidase beta in 12 consecutive patients age 7

245 each in combination with either thyrotropin alfa or thyroid hormone withdrawal before ablation.

246 r recombinant human thyrotropin (thyrotropin alfa) or thyroid hormone withdrawal.

247 tomatitis virus, a synthetic HCV genome, IFN alfa, or IFN beta.

248 ALFA outperformed the eleven compared methods providing

249 survival rate, 87%, vs. 63% with interferon alfa; P=0.005).

250 6 patients treated with pegylated interferon alfa (Peg-IFN) and adefovir.

251 previr, when given with pegylated interferon alfa (Peg-IFN) and ribavirin (RBV), result in a much hig

252 viral agent telaprevir, pegylated-interferon alfa (Peg-IFN), and ribavirin (RBV) significantly increa

253 is B respond to treatment with peginterferon alfa (PEG-IFN).

254 Pegylated interferon alfa (PEG-IFNalpha) is effective in only 25%-30% of pati

255 remained stagnant, with pegylated interferon alfa (PegIFN) plus ribavirin (RBV; PegIFN/RBV) entrenche

256 cal studies demonstrated pegvorhyaluronidase alfa (PEGPH20) degrades HA, thereby increasing drug deli

257 tic degradation of HA by pegvorhyaluronidase alfa (PEGPH20; PVHA) remodels the TME.

258 been randomly assigned to receive interferon alfa plus cytarabine (65.6%) and the short duration of t

259 ase to receive either imatinib or interferon alfa plus cytarabine.

260 Long-term treatment with interferon (IFN) alfa plus ribavirin decreases the proviral human immunod

261 evir to pegylated interferon (peginterferon) alfa plus ribavirin has improved sustained virological r

262 Combined with peginterferon-alfa plus ribavirin they offer genotype-1 infected patie

263 eligible for and intolerant of peginterferon alfa plus ribavirin.

264 adverse events associated with peginterferon alfa plus ribavirin.

265 ve; previous non-responders to peginterferon alfa plus ribavirin; or medically ineligible for, previo

266 In patients assigned to darbepoetin alfa, postrandomization systolic and diastolic blood pre

267 in NPs were then functionalised with dornase alfa (recombinant human deoxyribonuclease I, DNase), dem

268 inant human activated protein C (drotrecogin alfa) reduced mortality in patients with severe sepsis a

269 Interferon alfa remains the central treatment for chronic hepatitis

270 y, the combination of KY1070 and Darbepoetin alfa resulted in an EPO-sparing effect.

271 Treatment with epoetin alfa resulted in significant increases in hemoglobin (P<

272 telaprevir or boceprevir plus peginterferon alfa-ribavirin).

273 2 (100-800 mg/day) plus pegylated interferon alfa/ribavirin (peg-IFN/RBV) during a phase 2 trial.

274 ding a long-lived reduction in alglucosidase alfa-specific ADA.

275 Infants received 200 mg/kg of poractant alfa (surfactant) or air after randomization.

276 up, n=29), or switch to 0.2 mg/kg agalsidase-alfa (switch group) and were followed prospectively for

277 The ALFA test was in house validated for its precision, reco

278 th MPLA-plus-alum-adjuvanted Env protein (DP(ALFA)) The D(IP-10) P(ALFQ) vaccine regimen elicited hig

279 rt, of the 125 patients who received epoetin alfa, the composite outcome of death, MI, stroke, or ste

280 Sebelipase alfa therapy resulted in a reduction in multiple disease

281 The administration of the ESA epoetin alfa to critically ill trauma patients has been associat

282 Administration of epoetin alfa to older adult patients with heart failure and a pr

283 per deciliter) to receive either darbepoetin alfa (to achieve a hemoglobin target of 13 g per decilit

284 mucous hyperpigmentations during interferon alfa treatment have been reported, but they are consider

285 seven patients receiving ongoing sebelipase alfa treatment in LAL-CL04, the mean +/- standard deviat

286 econdary hyperpigmentation during interferon alfa treatment occurs as an adverse event in 21% of pati

287 rs aimed to evaluate the efficacy of epoetin alfa treatment on the outcome of OHCA patients in a phas

288 Interferon-alfa treatment-experienced patients (n = 42) were random

289 32 [99%]), irrespective of the peginterferon alfa used.

290 , the nebulization of 400 mg/kg of poractant alfa using a customized investigational eFlow-Neos nebul

291 Low-dose radioiodine plus thyrotropin alfa was as effective as high-dose radioiodine, with a l

292 The neutral effect of darbepoetin alfa was consistent across all prespecified subgroups.

293 d motor function also improved, and asfotase alfa was generally well tolerated.

294 Sebelipase alfa was well tolerated, with mostly mild adverse events

295 RBV and IFN alfa were effective against CHIKV as monotherapy at supr

296 However, RBV and IFN alfa were highly synergistic for antiviral effect when a

297 guidelines recommend 1 year of peginterferon alfa, which is effective in 25-30% of patients only.

298 ls that have been tolerized to alglucosidase alfa with methotrexate can transfer tolerance to naive h

299 safety of recombinant adenovirus interferon alfa with Syn3 (rAd-IFNalpha/Syn3), a replication-defici

300 at treating anemia with subcutaneous epoetin alfa would be associated with reverse ventricular remode

301 a standard clinical regimen of RBV plus IFN alfa would inhibit CHIKV burden by 2.5 log10 following 2